Twist Bioscience FY26 net loss widens 68% to $130.2 million; revenue rises 22% to $459.4 million
TWST•TWST•TWST•TWST•Twist Bioscience reported FY26 revenue of $459.4 million, up 22% year over year, and a net loss of $130.2 million, up 68%. It forecast FY27 revenue of $550 million to $560 million.
Twist Bioscience reported FY26 revenue of $459.4 million, up 22% year over year, while its net loss widened 68% to $130.2 million. In Q4, revenue rose 28% to $126.6 million and net loss narrowed 24% to $20.6 million.
Cash, cash equivalents and short-term investments totaled approximately $582 million at September 30, 2026, following approximately $425 million in equity proceeds. The company projected FY27 revenue of $550 million to $560 million and first-quarter revenue of $130 million to $132 million.
New launches included Twist Express Screening Antibodies and Twist MRD Express custom panels, with turnaround times of as little as one day.
